Takeda Raises Guidance On Divestments, Improved Velcade Outlook
Executive Summary
Takeda raises its guidance for both revenue growth and core profit after its first full fiscal quarter since acquiring Shire, citing delays in US generic competition and divestments. There are as yet no clear signs of what else may be sold off however.
You may also be interested in...
Ex Shire CEO Ornskov Resurfaces To Lead Skin Group Galderma
A group of investors has bought Nestlé Skin Health, renamed it Galderma to capitalize on its legacy in dermatology and put M&A veteran, former Shire CEO Flemming Ornskov, at its helm.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.